Elanco completes Kansas mAb manufacturing expansion
Analysis based on 7 articles · First reported Aug 26, 2026 · Last updated Aug 31, 2026
The expansion strengthens Elanco's manufacturing capacity for high-demand mAb products, potentially boosting revenue and market share in the animal health biologics segment. The positive demand outlook for Befrena and the company's innovation pipeline may support investor sentiment and stock performance.
Ceva Santé Animale Incorporated announced the on-time completion of a 25,000-square-foot manufacturing expansion at its United States — Elwood, United States — Kansas site, increasing monoclonal antibody (mAb) production capacity by more than four times. The $120 million investment includes a new pilot plant, quality control laboratory, and support spaces, with an additional $30 million planned through 2028 for warehousing, totaling $150 million. The expansion supports the phased launch of Befrena (tirnovetmab), a new anti-IL-31 mAb for canine allergic and atopic dermatitis, and the production of Trutect, the first approved therapeutic for canine parvovirus. Customer demand for Befrena is reportedly two times above expectations, and the company anticipates reaching unconstrained supply levels in early 2027. The project was led by design-build firm Burns & McDonnell. Elanco executives Grace McArdle, Jeff Simmons, and Koen De Brabander highlighted the expansion's role in meeting pet owner demand and advancing biologics innovation. The company also cited a survey of 1,409 U.S. pet owners indicating that pet health remains a top priority despite rising costs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard